As an accomplished physician, drug developer and biotech executive, Dr. Sukumar Nagendran brings to Solid more than 30 years of experience in key functional areas, including gene therapy development, clinical development strategy, medical affairs and diagnostics.
Sukumar Nagendran, M.D. has served as a member of Solid’s Board of Directors since September 2018.
Dr. Nagendran brings more than 25 years of experience in gene therapy development, clinical development strategy, medical affairs, diagnostics, payer strategy and commercialization of therapeutic products; also currently advising many other gene therapy and healthcare companies. Formerly of Jaguar Gene Therapy, AveXis, Quest Diagnostics and Pfizer.